Bambusa Therapeutics Files for IPO To Fund Eczema Drug Trials
A ipo & listings development with market-wide reach.
· NDTV Profit
Started in 2024, Bambusa secured its lead drug candidates through its earlier acquisition of assets from a unit of BioNTech SE, the first to treat atopic dermatitis, commonly known as eczema, and the second to treat other inflammatory disorders including respiratory and allergic diseases.
The analysis
Listing activity is a read on risk appetite — a hot primary market usually means a confident secondary one.
Related coverage
Vijay Kedia's portfolio stock under ₹150: This textile stock adds ₹3.7 crore to his wealth since IPO; Do you own?
Markets hit 6-month high in Oct on IT rally, Jio Platforms IPO frenzy
Gail's net profit zooms two-fold to ₹4,724 crore on robust volumes
After IPO listing, Jio Platforms Q2 results 2026 announced: Check ARPU, profit, revenue, EBITDA, Subscriber Base details
Atomberg Technologies IPO: Smart Fan-Maker Gets SEBI Nod For IPO, Plans Rs 450 Crore Fresh Issue